| | | 20,000+ Fresh Resumes Monthly | |
|
|
| |
Click here or scroll down to respond to this candidateCandidate's Name , Ph.D.Professor, Kansas University Medical Center,Senior Medical Writer, Responsum HealthPHONE NUMBER AVAILABLE, EMAIL AVAILABLE; EMAIL AVAILABLEOBJECTIVE:A challenging position of Medical Editor, which requires qualities of a strong technical leader and manager with excellent strategic and customer-focused leadership. The position is based on my experience in writing, reviewing and editing of scientific and medical manuscripts, abstracts and posters.SUMMARY OF QUALIFICATION:Extensive scientific knowledge, expertise in multiple biomedical areas. Experience in reviewing and editing scientific and medical texts based on work as editor in several journals.Expertise on the research of mechanisms of human diseases based on knowledge of biochemistry, molecular biology, neurology and pharmacology. Ability to clearly articulate scientific and clinical data in written and verbal communication,knowledge of AMA writing style and GPPIII and ICMJE guidelines. Experience with advancedwriting features in MS Word. Reliable time management skills and ability to manage expectations and time pressuresassociated with responding to client needs. As a researcher I perform literature searches and prepare summaries of literature. More than 20review articles are published in high ranking biomedical journals (see list of publications below).Excellent team-working and oral and written communication skills as evidenced by:oPreparing scientific data for publication: published ~75 review and research papers.oPreparing and giving presentations in either oral or poster formats:30 oral and poster presentations at a variety of scientific meetings.Writing grant proposals for federal institutions and private foundations. More than 10 of them were funded.Analytical skills:Troubleshooting and optimization of experimental procedures.Analysis of complex scientific results both for laboratory experiments and published data.Ability to clearly articulate scientific and clinical data in written and verbalcommunication. Experience with advanced writing features in MS Word and otherMicrosoft Office software.Editing and reviewing manuscripts for a peer-reviewed journals. Member of editorial boards in ~12 journals, reviewer in many biomedical journals.Team-work:Working in a goal-oriented collaborative environment.Leadership/managerial experience:oInstructed and supervised junior team members.oEstablished successful relationships with key opinion leaders, scientists and physicians.GRANT REVIEWER:Special Emphasis Panel/Scientific Review Group CSR/NIH, NEI, Challenge Grants (Panel 3).Reviewer of applications in NINDS/NIH, in response to RFA-NS-17-016 (Apr 2017).Reviewer in the Alzheimer's Association International Research Grant Program.Reviewer in Israel Science Foundation (ISF, 2017). Parkinsons UK; Glaucoma Foundation; The University of Kansas Alzheimers Disease Center; Midwest Biomedical Research Foundation (MBRF). Established successful relationships with key opinion leaders, scientists and physicians.MEMBERSHIPS, AWARDS:Member of R@D Committee, VA Medical Center, Kansas City.Committee Member-Reviewer, 5th International Conference on Biotechnology, Food and AnimalScience, Barcelona - ABIFA '16Honorable Organizing Committee Member, 2nd World Congress on Biopolymer, Manchester, UK,August 2016.Organizing Committee Member at Biopolymers and Bioplastics-2017, 5th International Conferenceand Exhibition on Biopolymers and Bioplastics, October 19-21, 2017, San Francisco, USA.Member of the Steering Committee of the Conference on Neurology, SCON Global Summit, LasVegas, USA 2019EDITOR, REVIEWER:Editor in Biomedical Research International, Associate Editor in Frontiers in Molecular Neuroscience,Frontiers of Cellular Biochemistry, Cell and Developmental Biology, Molecular Biosciences,Neurodegeneration.Certificate of Outstanding reviewer in Tissue and Cell, Archives of Biochemistry and Biophysics, 2017,2018. Certificate of Recognized reviewer in Tissue and Cell, Archives of Biochemistry andBiophysics, Experimental Eye Research, Molecular and Cellular Neuroscience, NeuroscienceLetters, FASEB and other journals.KEY RESEARCH CONTRIBUTIONS:2001- 2016 - Research biologist and Medical writer VA Medical Center, Kansas City, MO2009- current Professor, Kansas University Medical Center (joint appointment)2019- July 2020 Senior writer in Responsum Health (part time)2019- current - Editor in EaseEditing (part-time)Writing experience:Wrote and edited 20 manuscript for high ranking biomedical journals, all of them were published.Wrote and submitted 18 grant proposals, 5 of which were funded.Wrote and submitted 16 Abstracts and texts for oral presentations for national and Internationalmeetings all of which were presented.Research experience:Discovered a role of g-synuclein as the major contributor to the molecular mechanism of neurodegenerative diseases and cancer. Collaborated with 12 scientists on projects studying molecular mechanisms of neurological disorders.oInvestigated the role of g-synuclein as a regulator of gene expression and signaling pathways. Established its role as an initiator of the formation of protein aggregates in brain cells.oExplored the role of caveolins in retinal diseases, including retinal degeneration and glaucoma.oInvestigated how matrix metalloproteinases MMP-9 and MMP-2 are implicated in glaucoma and other eye diseases.oPrepared and submitted ~ 15 articles published in high ranking scientific journals.oPresented 20 oral and poster presentations at the Society for Neuroscience, ARVO and other meetingsoSubmitted several grant proposals, four of which were funded (two in federal institutions and two in private foundations.oOrganized and oversaw weekly laboratory meetings for research group.Associate Professor 1998 - 2001 Washington University, St. Louis, MOPerformed structure-function studies of synucleins role in health and human diseases. Studied matrix metalloproteinase 9 (MMP-9) in neurodegenerative diseases and cancer.Wrote and published 5 research papers as a major author. Presented 5 oral and poster presentations.Oversaw the work of a group of 4 scientists and technicians in the laboratory of retinal biology.Submitted several grant proposals, 3 of which were funded.Senior Investigator 1995-1998 University of Utah, UTIdentified a new retinal protein synoretin (g-synuclein) and investigated its role in health and diseases.Published two research papers and made 3 oral/poster presentation at ARVO meetingsAssistant Professor,1992-1995 Baylor College of Medicine, Houston, TXInvestigated genetic control of lipid metabolism and role of apolipoproteins in cardio-vascular diseasesEstablished a correlation between polymorphism in apolipoprotein III promoter region and predisposition to hyperlipoproteinemiaFound a role of apolipoprotein E (apo-E) in polymorphisms in coding region and the development of atherosclerosis and hyperlipoproteinemia.Published five articles in scientific journals.EDUCATION:Ph.D. Biochemistry and Molecular Biology, Moscow University, RussiaM.S. Biochemistry, Moscow University, RussiaB.S. Biochemistry, Moscow University, Moscow, RussiaPROFESSIONAL ACTIVITIES:Society for Neuroscience, 2010 - currentAssociation for Research of Vision and Ophthalmology (ARVO) 1999 -2012Invited reviewer for peer review journals 2012- currentChief Editor Biochemistry Research International; Member of Editorial Board in Frontiers in Molecular Neuroscience, Cell Biochemistry and other 10 Scientific Journals, 2014- currentSELECTED PEER-REVIEWED PUBLICATIONS:Chapters in the books.1 A. Surguchov. Molecular and cellular biology of synucleins. International Review of Cell andMolecular Biology, 270, PHONE NUMBER AVAILABLE2 A. Surguchov. Intracellular dynamics of synucleins: Here, there and everywhere. InternationalReview of Cell and Molecular Biology, 2015, 320:103-169.3 Surguchov A. in Protein Aggregation (Editor: DA Stein). Folding and unfolding of synucleins,Nova Science Publishers, 20114 Surguchov A. Advances in Brain Research (Eds: OB. Williams, GI Wilson). Two FacedMembers of the Family: The Synucleins, 2012.5 Surguchov A. Academic Editor. Synucleins: Biochemistry and role in diseases, 2018.IntechOpen.6 Surguchov A. Reviewer of the book "Frontiers in Clinical Drug Research - Alzheimer Disorders.Bentham Science Publishers. 2018.7 Emamzadeh FN and Surguchov A. Parkinsons disease. In: Predictive imagable biomarkers forbrain disorders. June 2019, Front. Neurol. Eds: PK. Mandal, L Ersland, doi:10.3389/fneur.2019.00583.8 Surguchov A. Biomarkers in Parkinsons disease. Chapter in a book: Towards TranslatingBiomarker Research of Neurodegenerative Diseases to Clinical Practice, Neuromethods Series bySpringer Nature. Eds. P. Peplow, B. Martinez, TA Gennarelli (accepted, 2020).Articles in peer reviewed journalsPronin AN, Morris AJ, Surguchov A, Benovic JL. Synucleins are a novel class of substrates for Gprotein-coupled receptor kinases. J Biol Chem. 2000, 275, PHONE NUMBER AVAILABLE (>420 citations).A. Surguchov, B. McMahon, E. Masliah, I. Surgucheva. Synucleins in ocular tissues. J Neurosci Res,2001, 65, 68-77A. Surguchov, RE. Palazzo, and I. Surgucheva. Gamma synucleins: subcellular localization inneuronal cells and effect on signal transduction. Cell Motility and Cytoskeleton, 2001, 49, 218-228Surgucheva I., McMahan B, F. Ahmed, Tomarev S, Wax MB, Surguchov A. 2002. Synucleins inglaucoma. J Neurosci Res, 68: 97-106.Surgucheva I, Sivak, JM, Fini ME, Palazzo RE and Surguchov A. Effect of g-synuclein expression onmatrix metalloproteinases. Arch Biochem Biophys. 2003, 410:167-176.Maurage CA, Ruchoux MM, De Vos R, Surguchov A, Destee A. Retinal involvement in dementia withLewy bodies: A clue to hallucinations? Ann Neurol. 2003, 54 (4):542-7.Snyder HM, Mensah K, Surgucheva I, Festoff B, Surguchov A, Wolozin B. -Synuclein preventsProteasomal inhibition by -synuclein but not g-synuclein. J Biol Chem, 2005. 4; 280:7562-9.Surgucheva, B. Yue, BC Park, S Tomarev and A. Surguchov. Interaction of myocilin with g-synucleinand its role in neurodegeneration in glaucoma. Cell Mol Neurobiol, 2005, 25, 6, 1009-33Surgucheva I, Ninkina N, Buchman VL, Grasing K, A. Surguchov. Protein aggregation in retinal cellsand approaches to cell protection. Cellular Molecular Neurobiology, 2005, 25, 6, 1051-1066.Surgucheva I, McMahon B., A. Surguchov. Dynamic intracellular localization of g-synuclein: a clueto its functions. Cell Motility and Cytoskeleton, 2006, 63, 8, 447-458.Surgucheva I, Surguchov A. 2008. g-Synuclein: Cell-Type Specific Promoter Activity and Binding toTranscription Factors. J Mol Neuroscience, 2008; 35(3):267-71.A. Surguchov. Molecular and cellular biology of synucleins. International Review of Cell andMolecular Biology, 2008, 270, 225-317.I Surgucheva, A Shnyra, J Goldberg, A. Weisman and A Surguchov. g-Synuclein as a marker of theretinal ganglion cells, Molecular Vision, 2008, 14:1540-1548.I Surgucheva, V Shestopalov and A Surguchov. Effect of g-synuclein silencing on apoptoticpathways in retinal ganglion cells. J Biol Chem, 2008, 284 (52): 36377-85.A. Surguchev and A. Surguchov. Conformational Diseases: Looking into the eyes. Brain ResearchBulletin, 2010, 81, 12-24Surgucheva I, Chidambaram K, Willoughby DA, Surguchov A. MicroRNA regulates MMP-9expression. J Ocular Biology, Diseases and Bioinformatics, 2010; 3: 41-52,Surgucheva I, McMahon B, Surguchov A. Patterns of synuclein expression throughout lensdevelopment. J Biophys Chem. 2010; 1: 12-18Surguchov A. in Protein Aggregation (Editor: DA. Stein). Folding and unfolding of Synucleins, NovaScience Publishers, 2011; 7, 179-192Surgucheva I and Surguchov A. Expression of caveolins in trabecular meshwork cells and itsimplication in pathogenesis of glaucoma. Molecular Vision 2011;17: 2878-2888Surgucheva I, Sharov V; Surguchov, A. g-Synuclein: Seeding of -Synuclein Aggregation andTransmission Between Cells. Biochemistry, 2012; 51(23):4743-54Surguchov A. Synucleins: are they two-edged swords? J Neurosci Res, 2013; 91 (2):161-6.Surguchov A. Parkinsons disease: Is there a light at the end of a tunnel? (Editorial). Advances inParkinsons Disease, Nov 2013, 2, 3, 116-117.Surgucheva I, Gunewardena S, Rao HS, Surguchov A. Cell-specific post-transcriptional regulation ofg-synuclein gene by micro-RNAs. PLOS One, Sep 2013, PONE-D-13-25172Surguchov A. What do synucleins do in the nucleus? (Editorial). Journal of Genetics, Molecular andBiology, 2014, 1, 1.Surguchov A. SNCG (synuclein, gamma). Atlas Genet Cytogenet Oncol Haematol. June 2014. URL:http://AtlasGeneticsOncology.org/Genes/SNCGID42343ch10q23.htmlSurgucheva I, Newell KL, Burns J and Surguchov A. New - and g-SynucleinImmunopathological Lesions in Human Brain. Acta Neuropathologica Com, 2014, 2: 132.Surgucheva I, He S, Sharma R, Rich M, Ninkina NN, Stahel P, Surguchov A. Role of synucleins intraumatic brain injury. Mol Cell Neurosci. 2014, 63, 114123.Surguchev A, Surguchov A. Effect of a-synuclein on membrane permeability and synaptictransmission: a clue to neurodegeneration? J Neurochemistry, 2015; 132 (6): 619-21Surguchov A. Intracellular dynamics of synucleins: Here, there and everywhere. International Reviewof Cell Molecular Biology, 2015; 320:103-169.Surguchov A. Atlas of Genetics and Cytogenetics in Oncology and Hematology, 2015, 19, 210-217.Surguchov A. Parkinsons disease and cancer: positive and negative associations. OncToday, 2016Surguchov A. Parkinsons disease: early diagnosis and association with melanoma. Brain Sci. 2016,6(2), 17; doi: 10.3390/brainsci6020017.Surguchov A. g-Synuclein as a cancer biomarker: viewpoint and new approaches.Oncomedicine, 2016, 1:1-3. doi:10.7150/oncm.16748.Surguchov A. Type-2 diabetes and Parkinsons disease: a cross-talk between main players. Journalof Diabetes Mellitus and Metabolic Syndrome, 2016, 1, 1-7.Roman A, M Kukharsky, A Surguchov, N Ninkina, V Skvortsova et al. g-Synuclein autoantibody inthe serum of patients with CVD and ALS. Annals Biol Sci, 2017, 472, 5.Surguchov A, Singh V, Surgucheva I, Sharma M, Singh V. New putative epigenetic mechanism ofepilepsy. Frontiers in Neurology, 2017, 8:3. doi: 10.3389/fneur.2017.00003.Surguchev AA and Surguchov A. Synucleins and gene expression: ramblers in a crowd or copsregulating traffic? Front. Mol. Neurosci. July 2017, 10, 1-7 224 doi: 10.3389/fnmol.2017.00224Surguchov A. -Synuclein Interacts with Lipoproteins in Plasma. Frontiers in MolecularNeuroscience, 2017, Nov 2, 2017. doi: 10.1007/sPHONE NUMBER AVAILABLEEmamzadeh FN and Surguchov A. Parkinsons disease: Biomarkers, Treatment, and Risk Factors .Frontiers in Neuroscience, Neurodegeneration, 12, 61230, August 2018https://doi.org/10.3389/fnins.2018.00612Surguchov A. Academic Editor of a Book: Synucleins: Biochemistry and role in diseases, 2018.IntechOpen.Surguchov A. Protein-DNA interaction: one step closer to understanding the mechanism ofneurodegeneration. October 2018, J Neurosci Res., DOI: 10.1002/jnr.24346.Surguchov A. Reviewer of the book chapter "Frontiers in Clinical Drug Research - AlzheimerDisorders. Bentham Science Publishers. 2018.Surguchev AA, Emamzadeh FN, Surguchov AA. Molecules. 2019 Jan 15;24(2). pii: E305. doi:10.3390/molecules24020305. PMID: 30650656Surguchev AA, Surguchov A. Integrins-A missing link in synuclein's pathogenic mechanism.J Neurosci Res. 2019 Jan 16. doi: 10.1002/jnr.24384. PMID: 30648275Surguchev AA, Emamzadeh FN, Surguchov A. Cell responses to extracellular a-synuclein.Molecules 2019, 24(2), 305; https://doi.org/10.3390/molecules24020305.Mojbafan M, Surguchov A, Amini M, Zeinali S. Genetic characteristic of patients with limb girdlemuscular dystrophy: an evidence of a founder effect. Biomed Res International, 2019, submitted.Surguchov A, Emamzadeh FN, Surguchov AA. Amyloidosis and longevity: a lesson from plants.Biology, 2019, 8(2), 43; https://doi.org/10.3390/biology8020043Emamzadeh FN and Surguchov A. Parkinsons disease. In: Predictive imagable biomarkers forbrain disorders. June 2019, Front. Neurol. Eds: PK. Mandal, and L Ersland.Surguchov A. Little pigeons can carry great messages in a book: Synucleins: Biochemistry androle in diseases, IntechOpen, 2019.Emamzadeh FN and Surguchov A. Parkinsons disease. In: Predictive imagable biomarkers forbrain disorders. June 2019, Front. Neurol. Eds: PK. Mandal, L Ersland, doi:10.3389/fneur.2019.00583.Surguchov A. Caveolin: a new link between diabetes and Alzheimers disease. Cell MolNeurobiology, 2020 Jan 23. doi: 10.1007/sPHONE NUMBER AVAILABLESurguchev AA, Surguchov A. A member of the ABC transporter family in healthy and ailing brain.(Editorial) Brain Sciences, February 2020, 10, 121; doi:10.3390/brainsci10020121Surguchov A. Analysis of protein conformational strains a key for new diagnostic methods.International Journal of Molecular Science, 2020, 21, 2801; doi:10.3390/ijms21082801Surguchov A. Biomarkers in Parkinsons disease. Chapter in a book: Towards TranslatingBiomarker Research of Neurodegenerative Diseases to Clinical Practice, Neuromethods Series bySpringer Nature. Eds. P. Peplow, B. Martinez, TA Gennarelli, 2020 (accepted).Surguchov A. When pandemic meets epidemic: COVID-19 and neurodegenerative diseases(Editorial) Biochemistry Research International, 2020 (accepted).Website: http://genetics1972.org/Andrei/Linkedin: https://LINKEDIN LINK AVAILABLE |
